Drug Update · Endocrinology

Insulin Glargine: Langlara Approved; Semglee Interchangeable with Lantus

August 24, 2026

Langlara approval date

April 2026

Langlara reference product

Lantus (insulin glargine)

Semglee status

Interchangeable with Lantus (insulin glargine)

FDA interchangeability guidance date

May 10, 2019

Clinical Perspective

For endocrinologists, prescribing clinicians, pharmacists, and advanced practice providers managing patients with diabetes, the 2026 FDA listing of Langlara as a biosimilar to Lantus and the documented interchangeability status of Semglee affect formulary considerations and potential pharmacy-level substitution policies ^[1]^[2]. The FDA’s interchangeability guidance and educational materials describe the regulatory basis for substitution and note that interchangeable biosimilars may be substituted without prescriber intervention depending on state pharmacy law, which clinicians and pharmacists must confirm locally ^[2]^[3]. How these approvals translate to local access, coverage, and out-of-pocket cost for individual patients remains a practice question: what are the anticipated formulary and substitution policies at your institution and payers?

Dr. Amit Desai, MBBS, MD (General Medicine), DM (Endocrinology) · Endocrinology

The FDA lists Langlara (insulin glargine-aldy) as an FDA-approved biosimilar to Lantus (insulin glargine) with an approval date of April 2026 ^[1]. Semglee (insulin glargine-yfgn) is listed in FDA materials as approved as an interchangeable biosimilar with Lantus; the FDA has described interchangeable biosimilars as substitutable without prescriber intervention depending on state pharmacy law ^[2].

Clinical Context

Biosimilars are biological products that are highly similar to an FDA-approved reference biologic and have no clinically meaningful differences in safety, purity, and potency, according to FDA guidance and educational materials ^[2]. The FDA states that approval of biosimilar products can improve access to care for patients by increasing the number of medication options and potentially lower costs through competition ^[1]. The agency has issued final guidance clarifying the pathway for demonstrating interchangeability, including considerations for repeated switching and the requirement that an interchangeable product produce the same clinical result in any given patient ^[3]. FDA materials note that interchangeable biosimilars may be substituted for the reference product without prescriber intervention, subject to state pharmacy law, and that additional data beyond biosimilarity are required to support interchangeability determinations ^[2]^[3].

Key Findings

The FDA lists Langlara (insulin glargine-aldy) as approved April 2026 as a biosimilar to Lantus (insulin glargine) ^[1].
FDA materials identify Semglee (insulin glargine-yfgn) as an interchangeable biosimilar with Lantus, meaning it met additional FDA requirements to support substitution without prescriber intervention under applicable state pharmacy law ^[2].
The FDA has characterized the approval of biosimilars generally as a mechanism that can increase patient access and potentially lower health care costs by encouraging market competition ^[1].
Separately, methodological literature on interchangeability and switching-study design identifies efficient crossover structures (for example, SBUwP-NSA designs) that can improve precision in switching assessments in biosimilar research and may inform study planning for interchangeability evaluations ^[4].
Clinical switching data from a non-insulin biologic (SB17 versus ustekinumab) showed comparable efficacy and safety up to Week 52 after switching, illustrating that randomized switching assessments have been used to evaluate clinical comparability and immunogenicity in biosimilar development programs ^[5].

Safety & Tolerability

Safety information was not available in the provided source excerpts.

Study Design

Langlara is listed by the FDA as an FDA-approved biosimilar to Lantus with an approval date of April 2026; the FDA is the approving regulatory body for this listing ^[1]. Details of the clinical trials or specific study designs supporting the Langlara approval were not available in the provided source excerpts. The FDA’s interchangeability guidance and related agency statements describe expectations for demonstrating interchangeability, including addressing switching and alternating use, but specific trial-level details for insulin interchangeability were not provided in the available excerpts ^[3]^[2].

FAQ

Q1 What is Langlara and what is it approved for?

Langlara (insulin glargine-aldy) is listed by the FDA as an FDA-approved biosimilar to Lantus (insulin glargine) with an approval date of April 2026. The FDA listing identifies Langlara as a biosimilar referencing Lantus as the reference product. Specific labeled indications as presented in the FDA listing were not further detailed in the provided source excerpts. Clinicians should consult current prescribing information for full dosing guidance.

Q2 How does an insulin biosimilar or an interchangeable insulin work?

The FDA defines a biosimilar as a biological product that is highly similar to and has no clinically meaningful differences from an FDA-approved reference product. An interchangeable biosimilar meets additional FDA requirements demonstrating it may be substituted for the reference product without the intervention of the prescriber under state pharmacy law. The provided excerpts describe these regulatory definitions and the interchangeability standard; mechanistic specifics beyond the regulatory definition were not available in the provided excerpts.

Q3 What is the recommended dose of Langlara or Semglee?

Information on specific recommended dosing for Langlara or Semglee was not available in the provided source excerpts. The FDA materials in the provided excerpts discuss regulatory approvals and interchangeability but do not include complete dosing instructions for these products. Clinicians should consult current prescribing information for full dosing guidance.

Q4 What are the side effects of these biosimilar insulins?

Information on the safety profiles or lists of adverse events specific to Langlara or Semglee was not available in the provided source excerpts. FDA educational materials note that biosimilars have the same potential side effects as the reference product when no clinically meaningful differences exist, but the provided excerpts do not enumerate specific adverse events for these insulin products. Clinicians should consult current prescribing information for full dosing guidance.

Clinicians should consult current prescribing information for full dosing guidance.

Insulin Glargine: Langlara Approved; Semglee Interchangeable with Lantus

Direct Clinical Takeaway & Evidence Summary

Insulin Glargine: Langlara Approved; Semglee Interchangeable with Lantus

Clinical Perspective

Clinical Context

Key Findings

Safety & Tolerability

Study Design

FAQ

References

Get weekly clinical updates for Endocrinology in your inbox.

Related Clinical Updates

FDA Approves Afrezza Label Update: Mealtime Dosage and Pump Transition

FDA Approves denosumab-adet (Ponlimsi) as Interchangeable Biosimilar to Prolia

Orforglipron (FOUNDAYO) FDA Approved for Obesity; 11.2% vs 2.1% Mean Weight Change in ATTAIN-1

Verified HCP Portal